Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma

Authors: Zhengrong Wu, Gang Li, Lirong Wu, Desheng Weng, Xiangping Li, Kaitai Yao

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Human Cripto-1, a member of the EGF-CFC family, is indispensable for early embryonic development. Cripto-1 plays an important oncogenic role during tumorigenesis and is overexpressed in a wide range of epithelial carcinomas, yet little is known about Cripto-1 in nasopharyngeal carcinoma (NPC). The aim of this study was to analyze the roles of Cripto-1 in the progression and clinical characteristics in NPC clinical samples and cell lines.

Methods

The expression of Cripto-1 at mRNA level was detected by the reverse transcription-polymerase chain reaction (RT-PCR) and real time RT-PCR, and western blot was used to examine the protein expression. Cripto-1 expression and its clinical characteristics were investigated by performing immunohistochemical analysis on a total of 37 NPC clinical tissue samples. Lentiviral vectors were constructed to get an efficient expression of anti-Cripto-1 siRNA in CNE-2 and C666-1 cells, with invalid RNAi sequence as control. After the inhibition of the endogenous Cripto-1, the growth, cell cycle and invasion of cells were detected by MTT, FACS and Boyden chamber assay respectively. Moreover, in vivo, the proliferation of the tumor cells was evaluated in xenotransplant nude mice model with whole-body visualizing instrument.

Results

The results of real-time RT-PCR and western blot showed that the expression level of Cripto-1 was markedly higher in NPC cell lines than that in the immortalized nasopharyngeal epithelial cell at both mRNA and protein levels. RT-PCR of 17 NPC tissues showed a high expression rate in 76.5% (13/17) cases. In an immunohistochemical study, Cripto-1 was found to express in 54.1% (20/37) cases of NPC. In addition, Cripto-1 overexpression was significantly associated with N classification (p = 0.034), distant metastasis (p = 0.036), and clinical stage (p = 0.007). Inhibition of endogenous Cripto-1 by lentivirus-mediated RNAi silencing technique suppressed NPC cell growth and invasion in vitro. In vivo, the average weight (p = 0.026) and volume (p = 0.044) of tumor in CNE-2/GFP+/Cripto-1- xenotransplant mice group were significantly lower than those in the control group. The Ki67 index was obviously lower in Cripto-1 RNAi treated tumors (p < 0.01).

Conclusion

Data of this study suggest that Cripto-1 overexpression is connected with the tumorigenesis and progression of NPC, lentivector-mediated RNAi might be feasible for the inhibition of the growth and invasion of NPC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL, et al: Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006, 6: 178-10.1186/1471-2407-6-178.CrossRefPubMedPubMedCentral Jia WH, Huang QH, Liao J, Ye W, Shugart YY, Liu Q, Chen LZ, Li YH, Lin X, Wen FL, et al: Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006, 6: 178-10.1186/1471-2407-6-178.CrossRefPubMedPubMedCentral
2.
go back to reference Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004, 64 (1): 316-321. 10.1158/0008-5472.CAN-03-2630.CrossRefPubMed Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004, 64 (1): 316-321. 10.1158/0008-5472.CAN-03-2630.CrossRefPubMed
3.
go back to reference Lo KW, Huang DP: Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002, 12 (6): 451-462. 10.1016/S1044579X02000883.CrossRefPubMed Lo KW, Huang DP: Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002, 12 (6): 451-462. 10.1016/S1044579X02000883.CrossRefPubMed
4.
go back to reference Bianco C, Normanno N, Salomon DS, Ciardiello F: Role of the cripto (EGF-CFC) family in embryogenesis and cancer. Growth Factors. 2004, 22 (3): 133-139. 10.1080/08977190410001723290.CrossRefPubMed Bianco C, Normanno N, Salomon DS, Ciardiello F: Role of the cripto (EGF-CFC) family in embryogenesis and cancer. Growth Factors. 2004, 22 (3): 133-139. 10.1080/08977190410001723290.CrossRefPubMed
5.
go back to reference Strizzi L, Postovit LM, Margaryan NV, Seftor EA, Abbott DE, Seftor RE, Salomon DS, Hendrix MJ: Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis. 2008, 29: 91-103.CrossRefPubMedPubMedCentral Strizzi L, Postovit LM, Margaryan NV, Seftor EA, Abbott DE, Seftor RE, Salomon DS, Hendrix MJ: Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis. 2008, 29: 91-103.CrossRefPubMedPubMedCentral
6.
go back to reference Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, Zhang GG, Hu Y, Lu AP, Li JY, et al: Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology. 2008, 52 (5): 560-568. 10.1111/j.1365-2559.2008.02971.x.CrossRefPubMed Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, Zhang GG, Hu Y, Lu AP, Li JY, et al: Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology. 2008, 52 (5): 560-568. 10.1111/j.1365-2559.2008.02971.x.CrossRefPubMed
7.
go back to reference Strizzi L, Bianco C, Normanno N, Salomon D: Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene. 2005, 24 (37): 5731-5741. 10.1038/sj.onc.1208918.CrossRefPubMed Strizzi L, Bianco C, Normanno N, Salomon D: Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene. 2005, 24 (37): 5731-5741. 10.1038/sj.onc.1208918.CrossRefPubMed
8.
go back to reference Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, et al: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res. 2006, 12 (17): 5158-5164. 10.1158/1078-0432.CCR-06-0274.CrossRefPubMed Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, et al: Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res. 2006, 12 (17): 5158-5164. 10.1158/1078-0432.CCR-06-0274.CrossRefPubMed
9.
go back to reference Sun Y, Strizzi L, Raafat A, Hirota M, Bianco C, Feigenbaum L, Kenney N, Wechselberger C, Callahan R, Salomon DS: Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol. 2005, 167 (2): 585-597.CrossRefPubMedPubMedCentral Sun Y, Strizzi L, Raafat A, Hirota M, Bianco C, Feigenbaum L, Kenney N, Wechselberger C, Callahan R, Salomon DS: Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol. 2005, 167 (2): 585-597.CrossRefPubMedPubMedCentral
10.
go back to reference Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, Guedez L, Salloum R, Ginsburg E, Sun Y, et al: Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst. 2005, 97 (2): 132-141.CrossRefPubMed Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, Guedez L, Salloum R, Ginsburg E, Sun Y, et al: Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst. 2005, 97 (2): 132-141.CrossRefPubMed
11.
go back to reference Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, et al: Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta. 2002, 1590 (1-3): 150-158. 10.1016/S0167-4889(02)00208-2.CrossRefPubMed Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, et al: Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta. 2002, 1590 (1-3): 150-158. 10.1016/S0167-4889(02)00208-2.CrossRefPubMed
12.
go back to reference Min H, Hong M, Ma J, Zhang E, Zheng Q, Zhang J, Zhang F, Su Y, Qiu F: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994, 30 (5): 1037-1042.CrossRefPubMed Min H, Hong M, Ma J, Zhang E, Zheng Q, Zhang J, Zhang F, Su Y, Qiu F: A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994, 30 (5): 1037-1042.CrossRefPubMed
13.
go back to reference Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001, 19 (5): 1350-1357.PubMed Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001, 19 (5): 1350-1357.PubMed
14.
go back to reference Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004, 10 (24): 8465-8471. 10.1158/1078-0432.CCR-04-0653.CrossRefPubMed Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K: Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004, 10 (24): 8465-8471. 10.1158/1078-0432.CCR-04-0653.CrossRefPubMed
15.
go back to reference Gray PC, Shani G, Aung K, Kelber J, Vale W: Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol. 2006, 26 (24): 9268-9278. 10.1128/MCB.01168-06.CrossRefPubMedPubMedCentral Gray PC, Shani G, Aung K, Kelber J, Vale W: Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol. 2006, 26 (24): 9268-9278. 10.1128/MCB.01168-06.CrossRefPubMedPubMedCentral
16.
go back to reference Tiscornia G, Singer O, Verma IM: Production and purification of lentiviral vectors. Nat Protoc. 2006, 1 (1): 241-245. 10.1038/nprot.2006.37.CrossRefPubMed Tiscornia G, Singer O, Verma IM: Production and purification of lentiviral vectors. Nat Protoc. 2006, 1 (1): 241-245. 10.1038/nprot.2006.37.CrossRefPubMed
17.
go back to reference Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y, Sanicola M, et al: Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol. 2004, 201 (2): 266-276. 10.1002/jcp.20062.CrossRefPubMed Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y, Sanicola M, et al: Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol. 2004, 201 (2): 266-276. 10.1002/jcp.20062.CrossRefPubMed
18.
go back to reference Wechselberger C, Strizzi L, Kenney N, Hirota M, Sun Y, Ebert A, Orozco O, Bianco C, Khan NI, Wallace-Jones B, et al: Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene. 2005, 24 (25): 4094-4105.CrossRefPubMed Wechselberger C, Strizzi L, Kenney N, Hirota M, Sun Y, Ebert A, Orozco O, Bianco C, Khan NI, Wallace-Jones B, et al: Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene. 2005, 24 (25): 4094-4105.CrossRefPubMed
19.
go back to reference Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, Xing PX, Gillett DJ: Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol. 2007, 33 (4): 438-443. 10.1016/j.ejso.2006.10.014.CrossRefPubMed Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, Xing PX, Gillett DJ: Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol. 2007, 33 (4): 438-443. 10.1016/j.ejso.2006.10.014.CrossRefPubMed
20.
go back to reference Brandt R, Normanno N, Gullick WJ, Lin JH, Harkins R, Schneider D, Jones BW, Ciardiello F, Persico MG, Armenante F, et al: Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. J Biol Chem. 1994, 269 (25): 17320-17328.PubMed Brandt R, Normanno N, Gullick WJ, Lin JH, Harkins R, Schneider D, Jones BW, Ciardiello F, Persico MG, Armenante F, et al: Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. J Biol Chem. 1994, 269 (25): 17320-17328.PubMed
21.
go back to reference Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, Wechselberger C, Arra C, Strizzi L, Sanicola M, et al: Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol. 2004, 198 (1): 31-39. 10.1002/jcp.10375.CrossRefPubMed Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, Wechselberger C, Arra C, Strizzi L, Sanicola M, et al: Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol. 2004, 198 (1): 31-39. 10.1002/jcp.10375.CrossRefPubMed
22.
go back to reference Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ, Salomon DS: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA. 1991, 88 (17): 7792-7796. 10.1073/pnas.88.17.7792.CrossRefPubMedPubMedCentral Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ, Salomon DS: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA. 1991, 88 (17): 7792-7796. 10.1073/pnas.88.17.7792.CrossRefPubMedPubMedCentral
23.
go back to reference Ertoy D, Ayhan A, Sarac E, Karaagaoglu E, Yasui W, Tahara E: Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas. Eur J Cancer. 2000, 36 (8): 1002-1007. 10.1016/S0959-8049(00)00033-2.CrossRefPubMed Ertoy D, Ayhan A, Sarac E, Karaagaoglu E, Yasui W, Tahara E: Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas. Eur J Cancer. 2000, 36 (8): 1002-1007. 10.1016/S0959-8049(00)00033-2.CrossRefPubMed
24.
go back to reference Cheng SK, Olale F, Bennett JT, Brivanlou AH, Schier AF: EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 2003, 17 (1): 31-36. 10.1101/gad.1041203.CrossRefPubMedPubMedCentral Cheng SK, Olale F, Bennett JT, Brivanlou AH, Schier AF: EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GDF1. Genes Dev. 2003, 17 (1): 31-36. 10.1101/gad.1041203.CrossRefPubMedPubMedCentral
25.
go back to reference Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, et al: Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003, 112 (4): 575-587.CrossRefPubMedPubMedCentral Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, et al: Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003, 112 (4): 575-587.CrossRefPubMedPubMedCentral
26.
go back to reference Kannan S, De Santis M, Lohmeyer M, Riese DJ, Smith GH, Hynes N, Seno M, Brandt R, Bianco C, Persico G, et al: Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem. 1997, 272 (6): 3330-3335. 10.1074/jbc.272.6.3330.CrossRefPubMed Kannan S, De Santis M, Lohmeyer M, Riese DJ, Smith GH, Hynes N, Seno M, Brandt R, Bianco C, Persico G, et al: Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem. 1997, 272 (6): 3330-3335. 10.1074/jbc.272.6.3330.CrossRefPubMed
27.
go back to reference Ebert AD, Wechselberger C, Frank S, Wallace-Jones B, Seno M, Martinez-Lacaci I, Bianco C, De Santis M, Weitzel HK, Salomon DS: Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res. 1999, 59 (18): 4502-4505.PubMed Ebert AD, Wechselberger C, Frank S, Wallace-Jones B, Seno M, Martinez-Lacaci I, Bianco C, De Santis M, Weitzel HK, Salomon DS: Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res. 1999, 59 (18): 4502-4505.PubMed
28.
go back to reference Morkel M, Huelsken J, Wakamiya M, Ding J, Wetering van de M, Clevers H, Taketo MM, Behringer RR, Shen MM, Birchmeier W: Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development. 2003, 130 (25): 6283-6294. 10.1242/dev.00859.CrossRefPubMed Morkel M, Huelsken J, Wakamiya M, Ding J, Wetering van de M, Clevers H, Taketo MM, Behringer RR, Shen MM, Birchmeier W: Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development. 2003, 130 (25): 6283-6294. 10.1242/dev.00859.CrossRefPubMed
29.
go back to reference Tao Q, Yokota C, Puck H, Kofron M, Birsoy B, Yan D, Asashima M, Wylie CC, Lin X, Heasman J: Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos. Cell. 2005, 120 (6): 857-871. 10.1016/j.cell.2005.01.013.CrossRefPubMed Tao Q, Yokota C, Puck H, Kofron M, Birsoy B, Yan D, Asashima M, Wylie CC, Lin X, Heasman J: Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos. Cell. 2005, 120 (6): 857-871. 10.1016/j.cell.2005.01.013.CrossRefPubMed
30.
go back to reference Normanno N, Tortora G, De Luca A, Pomatico G, Casamassimi A, Agrawal S, Mendelsohn J, Bianco AR, Ciardiello F: Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep. 1999, 6 (5): 1105-1109.PubMed Normanno N, Tortora G, De Luca A, Pomatico G, Casamassimi A, Agrawal S, Mendelsohn J, Bianco AR, Ciardiello F: Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep. 1999, 6 (5): 1105-1109.PubMed
31.
go back to reference Hu XF, Li J, Yang E, Vandervalk S, Xing PX: Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer. 2007, 96 (6): 918-927. 10.1038/sj.bjc.6603641.CrossRefPubMedPubMedCentral Hu XF, Li J, Yang E, Vandervalk S, Xing PX: Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer. 2007, 96 (6): 918-927. 10.1038/sj.bjc.6603641.CrossRefPubMedPubMedCentral
Metadata
Title
Cripto-1 overexpression is involved in the tumorigenesis of nasopharyngeal carcinoma
Authors
Zhengrong Wu
Gang Li
Lirong Wu
Desheng Weng
Xiangping Li
Kaitai Yao
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-315

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine